¼¼°èÀÇ ³ú¿° Ä¡·á ½ÃÀå
Encephalitis Treatment
»óǰÄÚµå : 1774810
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 478 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ³ú¿° Ä¡·á ½ÃÀåÀº 2030³â±îÁö 275¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 216¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ³ú¿° Ä¡·á ¼¼°è ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 4.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 275¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ 1Â÷ ³ú¿°Àº CAGR 4.8%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 182¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2Â÷ ³ú¿° ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 2.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 59¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ³ú¿° Ä¡·á ½ÃÀåÀº 2024³â¿¡ 59¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 57¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 7.7%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.6%¿Í 3.2%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.4%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ³ú¿° Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

³ú¿°À̶õ ¹«¾ùÀ̸ç, ¿Ö È¿°úÀûÀÎ Ä¡·á°¡ Áß¿äÇѰ¡?

³ú¿°Àº ³úÀÇ ¿°ÁõÀ» Ư¡À¸·Î ÇÏ´Â ½É°¢ÇÑ ½Å°æÁúȯÀ¸·Î, ¹ÙÀÌ·¯½º °¨¿°, ÀÚ°¡¸é¿ªÁúȯ ¶Ç´Â ¼¼±Õ¼º º´¿øÃ¼¿¡ ÀÇÇØ ¹ß»ýÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ³ú¿°À» Ä¡·áÇÏÁö ¾Ê°í ¹æÄ¡Çϸé Àå±âÀûÀÎ ½Å°æ ÇÕº´Áõ, °æ·Ã, ÀÎÁö ±â´É Àå¾Ö¸¦ À¯¹ßÇÏ°í ½ÉÇÒ °æ¿ì »ç¸Á¿¡ À̸¦ ¼öµµ ÀÖ½À´Ï´Ù. ÀϺ»³ú¿°, ¿þ½ºÆ® ³ªÀÏ ¹ÙÀÌ·¯½º, ÁöÄ« ¹ÙÀÌ·¯½º µî ¸ð±â ¸Å°³ ³ú¿° ¹ÙÀÌ·¯½º Áõ°¡·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î ÀÌ ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´Ü¼ø Ç츣Æä½º ¹ÙÀÌ·¯½º(HSV) À¯¹ß ³ú¿°°ú ÀÚ°¡¸é¿ª¼º ³ú¿°ÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ È¿°úÀûÀÎ Ç×¹ÙÀÌ·¯½º ¹× ¸é¿ª Á¶Àý ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR) °Ë»ç, ³úô¼ö¾× ºÐ¼®, MRI ¿µ»óÁø´Ü µî Á¶±â Áø´Ü¹ýÀÌ °¡´ÉÇØÁü¿¡ µû¶ó Ä¡·á ¼ºÀûÀÌ Çâ»óµÇ°í Àû½Ã¿¡ ÀÇ·á °³ÀÔÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. º´¿ø°ú ¿¬±¸±â°üµéÀº ƯÈ÷ ¾Æ½Ã¾Æ, ¾ÆÇÁ¸®Ä«, ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ °íÀ§Çè Áö¿ª¿¡¼­ ¹ÙÀÌ·¯½º¼º ³ú¿°¿¡ ´ëÇ×Çϱâ À§ÇÑ Ç¥ÀûÄ¡·áÁ¦¿Í ¹é½Å °³¹ß¿¡ Àû±ØÀûÀ¸·Î ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸ð±â ¸Å°³ ³ú¿° ¹ß»ýÀ» ¾ïÁ¦Çϱâ À§ÇÑ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ ¹× °øÁߺ¸°Ç ³ë·Â¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

³ú¿° Ä¡·áÀÇ Ãֽе¿ÇâÀº?

ÃÖ±Ù ³ú¿° Ä¡·áÀÇ ¹ßÀü¿¡´Â »õ·Î¿î Ç×¹ÙÀÌ·¯½ºÁ¦, ´ÜÀÏŬ·ÐÇ×ü, ¸é¿ªÁ¶Àý¿ä¹ý µîÀÌ ÀÖ½À´Ï´Ù. ¹ÙÀÌ·¯½º¼º ³ú¿°ÀÇ °æ¿ì, ´Ü¼ø Ç츣Æä½º ¹ÙÀÌ·¯½º(HSV) ³ú¿°ÀÇ ÁÖ¿ä Ä¡·áÁ¦´Â ¾Æ½ÃŬ·Î¹öÀ̸ç, »õ·Î¿î ±¤¹üÀ§ Ç×¹ÙÀÌ·¯½ºÁ¦°¡ ½ÅÈï ¹ÙÀÌ·¯½º ±ÕÁÖÀÇ Ä¡·áÁ¦·Î °ËÅäµÇ°í ÀÖ½À´Ï´Ù. ¸é¿ª¿ä¹ý, ƯÈ÷ ¸é¿ª±Û·ÎºÒ¸° Á¤¸ÆÁÖ»ç(IVIG)¿Í ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å´Â ÀÚ°¡¸é¿ª¼º ³ú¿° Ä¡·á¿¡ À¯¸ÁÇÑ °á°ú¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ¿¬±¸ÀÚµéÀº ³ú¿°À» À¯¹ßÇÏ´Â ¹ÙÀÌ·¯½º¸¦ ¿¹¹æÇϱâ À§ÇÑ mRNA ±â¹Ý ¹é½Å°ú Â÷¼¼´ë ¸é¿ª Àü·«À» °³¹ßÇϰí ÀÖÀ¸¸ç, AI¸¦ Ȱ¿ëÇÑ Áø´Ü Ç÷§ÆûÀº Á¶±â ¹ß°ß°ú Ä¡·á °èȹÀ» °³¼±Çϰí ÇÕº´Áõ À§ÇèÀ» ÁÙÀ̱â À§ÇØ AI¸¦ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á Á¢±Ù¹ýÀÇ ÅëÇÕ¿¡ ´ëÇÑ Á߿伺ÀÌ °­Á¶µÇ¸é¼­ ³ú¿° °ü¸®ÀÇ Çõ½ÅÀ» ÃËÁøÇÏ°í »ýÁ¸À²°ú Àå±âÀûÀΠȸº¹ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

³ú¿° Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

³ú¿° Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ¹ÙÀÌ·¯½º ¹ß»ý Áõ°¡, Èñ±Í ½Å°æÁúȯ ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø Áõ°¡, Ç×¹ÙÀÌ·¯½º ¹× ¸é¿ª¿ä¹ý Ä¡·áÀÇ ¹ßÀüÀ¸·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ƯÈ÷ °íÀ§Çè Áö¿ª¿¡¼­ÀÇ ¹é½Å ÇÁ·Î±×·¥ È®´ë´Â Áúº´ ¿¹¹æ¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í¿Í ÇコÄɾî ÅõÀÚ·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å°æÇÐ ¿¬±¸¿¡¼­ÀÇ AI Ȱ¿ë Áõ°¡, Áø´Ü ´É·ÂÀÇ Çâ»ó, Á¦¾àȸ»ç¿ÍÀÇ Á¦ÈÞ¸¦ ÅëÇÑ ÀǾàǰ °³¹ßÀÌ ½ÃÀå °³Ã´À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Á¤ºÎÀÇ °øÁß º¸°Ç¿¡ ´ëÇÑ ³ë·Â, Àü¿°º´ ´ëÃ¥ ÇÁ·Î±×·¥, ¸ð±â ÅðÄ¡ ´ëÃ¥ÀÇ ±ÞÁõµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ½Å°æÇÐÀû ÇÕº´Áõ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡µµ ³ú¿° Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃŰ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¿¬±¸°¡ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó À¯ÀüÀÚ Ä¡·á, »ý¹°ÇÐÀû Á¦Á¦, °³ÀÎ ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ýÀÇ È¹±âÀûÀÎ ¹ßÀüÀ¸·Î ³ú¿° ȯÀÚÀÇ Ä¡·á ¿É¼ÇÀÌ ´õ¿í È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

Áúȯ À¯Çü(¿ø¹ß¼º ³ú¿°, ÀÌÂ÷¼º ³ú¿°);Ä¡·á¹ý(Ç×¹ÙÀÌ·¯½ºÁ¦, ½ºÅ×·ÎÀ̵å ÁÖ»ç, Ç×»ýÁ¦, ¸é¿ª±Û·ÎºÒ¸° ¿ä¹ý, Ç÷Àå äÁý, ±âŸ Ä¡·á¹ý);Åõ¿© °æ·Î(°æ±¸, ºñ°æ±¸, ±âŸ);ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, Àü¹® Ŭ¸®´Ð, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Encephalitis Treatment Market to Reach US$27.5 Billion by 2030

The global market for Encephalitis Treatment estimated at US$21.6 Billion in the year 2024, is expected to reach US$27.5 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Primary encephalitis, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$18.2 Billion by the end of the analysis period. Growth in the Secondary encephalitis segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.9 Billion While China is Forecast to Grow at 7.7% CAGR

The Encephalitis Treatment market in the U.S. is estimated at US$5.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.7 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Encephalitis Treatment Market - Key Trends & Drivers Summarized

What Is Encephalitis, and Why Is Effective Treatment Critical?

Encephalitis is a severe neurological condition characterized by inflammation of the brain, often caused by viral infections, autoimmune disorders, or bacterial pathogens. If left untreated, encephalitis can lead to long-term neurological complications, seizures, cognitive impairments, and, in severe cases, fatality. The growing incidence of mosquito-borne encephalitis viruses such as Japanese encephalitis, West Nile virus, and Zika virus has contributed to the increasing global burden of this disease. Additionally, the rising prevalence of herpes simplex virus (HSV)-induced encephalitis and autoimmune encephalitis has led to higher demand for effective antiviral and immunomodulatory therapies.

The availability of early diagnosis methods, such as polymerase chain reaction (PCR) testing, cerebrospinal fluid analysis, and MRI imaging, has improved treatment outcomes, enabling timely medical intervention. Hospitals and research institutions are actively investing in targeted therapies and vaccine development to combat viral-induced encephalitis, particularly in high-risk regions of Asia, Africa, and Latin America. The increasing focus on preventive vaccination programs and public health initiatives to curb mosquito-borne encephalitis outbreaks has also fueled market growth.

What Are the Latest Advancements in Encephalitis Treatment?

Recent advancements in encephalitis treatment include novel antiviral agents, monoclonal antibodies, and immune-modulating therapies. For viral encephalitis, acyclovir remains the primary treatment for herpes simplex virus (HSV) encephalitis, while newer broad-spectrum antiviral drugs are being explored for treating emerging viral strains. Immunotherapy, particularly intravenous immunoglobulin (IVIG) and corticosteroids, has shown promising results in managing autoimmune encephalitis cases.

Additionally, researchers are developing mRNA-based vaccines and next-generation immunization strategies to prevent encephalitis-causing viruses, particularly in endemic regions. AI-powered diagnostic platforms are also improving early detection and treatment planning, reducing the risk of complications. The growing emphasis on integrating precision medicine approaches is expected to drive innovation in encephalitis management, improving survival rates and long-term recovery outcomes.

What Is Driving the Growth of the Encephalitis Treatment Market?

The growth in the encephalitis treatment market is driven by rising viral outbreaks, increased funding for rare neurological disease research, and advancements in antiviral and immunotherapy treatments. The expansion of vaccine programs, particularly in high-risk regions, has led to greater disease prevention awareness and healthcare investments. Additionally, the increasing use of AI in neurology research, improved diagnostic capabilities, and pharmaceutical collaborations in drug development has propelled market expansion.

The surge in government public health initiatives, pandemic preparedness programs, and mosquito control measures has also contributed to market growth. The rising geriatric population, who are more susceptible to neurological complications, is another significant factor increasing demand for encephalitis treatments. As research continues to evolve, breakthroughs in gene therapy, biologics, and personalized medicine approaches are expected to further expand treatment options for encephalitis patients.

SCOPE OF STUDY:

The report analyzes the Encephalitis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Primary encephalitis, Secondary encephalitis); Treatment (Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis, Other treatments); Administration Route (Oral, Parenteral, Others); End-Use (Hospitals, Specialty clinics, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â